Literature DB >> 1511808

Islet cell antibody heterogeneity among type 1 (insulin-dependent) diabetic patients.

J Timsit1, S Caillat-Zucman, H Blondel, P Chédin, J F Bach, C Boitard.   

Abstract

Conventional detection of islet cell antibodies is based on indirect immunofluorescence performed on frozen human pancreas sections. The number and nature of epitopes recognized by antibodies detected by such techniques are unknown. To determine the existence of heterogeneous fluorescence patterns of islet cell antibodies on pancreatic sections, we selected two sera showing a distinctive granular fluorescence. We then tested random sera from patients with Type 1 (insulin-dependent) diabetes mellitus for their ability to block ultimate binding of fluorescein isothiocyanate-labelled immunoglobulins purified from these two sera with a characteristic granular pattern. Among 102 subjects with recent-onset Type 1 diabetes, 79 had detectable anti-islet cell antibodies; 21 showed complete blockade of the binding to islets of granular fluorescein isothiocyanate-labelled immunoglobulins. The majority of these 21 patients were women carrying a DR3 non-DR4 DQB1*0201 allele, with under-representation of DRB1*0402 and 0405. Discrimination between islet cell antigenic specificities may help in identifying islet cell autoantibodies in autoimmune Type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1511808     DOI: 10.1007/bf00429102

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  9 in total

1.  Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays.

Authors:  E Bonifacio; C Boitard; H Gleichmann; M A Shattock; J L Molenaar; G F Bottazzo
Journal:  Diabetologia       Date:  1990-12       Impact factor: 10.122

2.  Application of HLA-DR oligotyping to 110 kidney transplant patients with doubtful serological typing.

Authors:  J M Tiercy; C Goumaz; B Mach; M Jeannet
Journal:  Transplantation       Date:  1991-05       Impact factor: 4.939

3.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.

Authors:  G F Bottazzo; A Florin-Christensen; D Doniach
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

4.  Improved sensitivity of islet cell cytoplasmic antibody assay in diabetics.

Authors:  C Pilcher; R B Elliott
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

5.  Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes.

Authors:  R Gianani; A Pugliese; S Bonner-Weir; A J Shiffrin; J S Soeldner; H Erlich; Z Awdeh; C A Alper; R A Jackson; G S Eisenbarth
Journal:  Diabetes       Date:  1992-03       Impact factor: 9.461

6.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase.

Authors:  S Baekkeskov; H J Aanstoot; S Christgau; A Reetz; M Solimena; M Cascalho; F Folli; H Richter-Olesen; P De Camilli; P D Camilli
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

Review 7.  Novel considerations on the antibody/autoantigen system in type I (insulin-dependent) diabetes mellitus.

Authors:  G F Bottazzo; S Genovese; E Bosi; B M Dean; M R Christie; E Bonifacio
Journal:  Ann Med       Date:  1991-10       Impact factor: 4.709

8.  In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis.

Authors:  G F Bottazzo; B M Dean; J M McNally; E H MacKay; P G Swift; D R Gamble
Journal:  N Engl J Med       Date:  1985-08-08       Impact factor: 91.245

9.  Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes.

Authors:  E Bonifacio; P J Bingley; M Shattock; B M Dean; D Dunger; E A Gale; G F Bottazzo
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

  9 in total
  6 in total

1.  Anti-GAD monoclonal antibody delays the onset of diabetes mellitus in NOD mice.

Authors:  V Menard; H Jacobs; H S Jun; J W Yoon; S W Kim
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

2.  Association between HLA and islet cell antibodies in diabetic patients with a mitochondrial DNA mutation at base pair 3243.

Authors:  T Kobayashi; Y Oka; H Katagiri; A Falorni; A Kasuga; I Takei; K Nakanishi; T Murase; K Kosaka; A Lernmark
Journal:  Diabetologia       Date:  1996-10       Impact factor: 10.122

3.  Subtype of islet cell antibodies and slowly progressive beta-cell failure.

Authors:  T Kobayashi; K Nakanishi; T Murase; K Kosaka
Journal:  Diabetologia       Date:  1993-01       Impact factor: 10.122

4.  Quantification of human cytoplasmic islet-cell antibodies which cross-react with mouse pancreas: a follow-up study in type 1 (insulin-dependent) diabetic patients and in first-degree relatives.

Authors:  P Saï; A Elmansour; M Audrain; B Charbonnel; S Bardet
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

5.  Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity.

Authors:  E Bonifacio; S Genovese; S Braghi; E Bazzigaluppi; V Lampasona; P J Bingley; L Rogge; M R Pastore; E Bognetti; G F Bottazzo
Journal:  Diabetologia       Date:  1995-07       Impact factor: 10.122

6.  Combined analysis of islet cell antibodies which cross-react with mouse pancreas, antibodies to the M(r) 64,000 islet protein, and antibodies to glutamate decarboxylase in subjects at risk for IDDM.

Authors:  L Chaillous; M Delamaire; A Elmansour; D Maugendre; V Rohmer; M G Joseph; P Lecomte; J M Limal; B Charbonnel; H Allannic
Journal:  Diabetologia       Date:  1994-05       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.